ERBB2 and breast cancer: Beyond the lack of evidence demonstrating efficacy of IT over IV trastuzumab for HER2+ BC LM, a number of complications are associated with IT administration, such as drug-induced aseptic meningitis (DIAM) and infection of the IT reservoir through which the agents are administered.